The ONE Forum 2021: On-demand session
Over the last several years, there has been increasing global investment in the development of novel allogeneic cell and gene therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 allogeneic cellular therapies are under development across the globe, many of which are focused on hematological malignancies that have traditionally been treated with BMT and HSCT (The Clinical Pipeline for Cancer Cell Therapies, Nature Reviews Drug Discovery, June 2021). While the majority of emerging therapies are autologous, there is rapid growth in the clinical development of allogeneic approaches that might one day offer either a replacement or complement to autologous approaches.
In this session, a panel of industry and clinical experts explore the promise and risks associated with allogeneic cell therapy approaches.
Sarah Cooley, MD, MS
Senior Vice President, Clinical Translation
St. Jude Children’s Research Hospital
Chair of the Department of Bone Marrow Transplant and Cellular Therapy
Children’s Hospital of Philadelphia
Chief of the Cellular Therapy and Transplant Section
Be the Match BioTherapies®
Senior Vice President, Sales – Commercial Entities